MPM BioImpact Nachrichten und Aktivitäten
Führungskräfte
Siehe das Organigramm mit seine 29 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei MPM BioImpact
- Christiana Bardon, Managing Partner
- Ansbert Gadicke, Managing Partner
- Matthew Roden, Entrepreneur Partner
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von MPM BioImpact nachzuverfolgen.
Fond
MPM BioImpact hat 1.642 Konkurrenten , einschließlich Griffin Gaming Partners (USA), BlackRock (USA) und KKR (USA).
Popular M&A news in Fond
- DigitalBridge Group has announced the acquisition of ArcLight Capital Partners (veröffentlicht am 3, Juni 2026).
- Prime Capital Financial hat Access Capital Partners erworben (veröffentlicht am 2, Juni 2026).
- Frazier Healthcare Partners hat Altruix erworben (veröffentlicht am 29, Mai 2026).
Andere vorgeschlagene Kontakte der Fond branche
Nachrichten
Neueste Pressemitteilungen nach MPM BioImpact
- The Endpoints 11: Umoja Biopharma looks to finally break through the barriers that restrict CAR-T
- Reunion Neuroscience | Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
- Entrada Therapeutics | Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45
- Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | Cullinan Therapeutics, Inc.
- Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types - Aktis
- DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved | DBV Technologies
- Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy | Cullin
- Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
- MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner
- MPM BioImpact Appoints Brian Shuster, Experienced in Healthcare Corporate Development, as Entrepreneur Partner
- View more press releases Close
Social media about MPM BioImpact
- MPM BioImpact auf Wikipedia, Google News & Yahoo Finance
- MPM BioImpact auf LinkedIn, X (Twitter) & YouTube
